AIM
ADAP

Aigen Investment Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Aigen Investment Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,776
Closed -$43K – 512
2021
Q4 		$43K Buy
+11,776
New +$53.6K ﹤0.01% 1014

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aigen Investment Management's ADAP Position: Q1 2022 in Review

Aigen Investment Management sold out of Adaptimmune Therapeutics (ADAP) in Q1 2022, closing a stake of 11,776 shares — an estimated $43K sold.

Aigen Investment Management first reported a position in ADAP in Q4 2021 and held it in 1 quarter. The position peaked at $43K in Q4 2021. 80 funds tracked by Wall St. Rank hold ADAP as of Q1 2022.

  • Aigen Investment Management reported no remaining Adaptimmune Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Aigen Investment Management sold 11,776 Adaptimmune Therapeutics shares in Q1 2022, an estimated $43K.
  • Aigen Investment Management first reported a position in Adaptimmune Therapeutics in Q4 2021 and held it in 1 quarter.
  • Aigen Investment Management's Adaptimmune Therapeutics position peaked at $43K in Q4 2021.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2022.

Based on Aigen Investment Management's 13F filing for Q1 2022, filed 5 May 2022.